Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg in virologic suppressed HIV-infected Thai adults: a multicentre, randomized, open-label trial: LASA

Torsak Bunupuradah,Sasisopin Kiertiburanakul,Anchalee Avihingsanon,Ploenchan Chetchotisakd,Malee Techapornroong,Niramon Leerattanapetch,Pacharee Kantipong,Chureeratana Bowonwatanuwong, Sukit Banchongkit,Virat Klinbuayaem, Sripetcharat Mekviwattanawan,Sireethorn Nimitvilai,Supunnee Jirajariyavej,Wisit Prasithsirikul,Warangkana Munsakul,Sorakij Bhakeecheep, Sushada Chaivooth,Praphan Phanuphak,David A. Cooper,Tanakorn Apornpong,Stephen J. Kerr,Sean Emery,Kiat Ruxrungtham

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2015）

Cited 0|Views24
No score
Key words
atazanavir/ritonavir,atazanavir/ritonavir,non-inferior,hiv-infected,open-label
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined